On this page of StockholderLetter.com we present the latest annual shareholder letter from AMICUS THERAPEUTICS, INC. — ticker symbol FOLD. Reading current and past FOLD letters to shareholders can bring important insights into the investment thesis.

 •  4/24/2024 Letter Continued (Full PDF)
 •  4/26/2023 FOLD Stockholder Letter
 •  More "Biotechnology" Category Stockholder Letters
 •  FOLD Benford's Law Stock Score = 48

FOLD Shareholder/Stockholder Letter Transcript:

An Extraordinary
Story in Rare
Disease
20 23 AN N UAL R EPORT

To Our Shareholders
Everyday Amicus is driven by a shared
sense of purpose and commitment to
people around the world living with
a rare disease. Our work is founded
in the belief that every person living
with a rare disease deserves access
to effective treatments and that
together we can be the difference.
Our accomplishments in 2023 represent the dedication
Amicus brings to the rare disease community as we
continued our mission of transforming the lives of
people living with rare diseases. The accomplishments
were transformational and pillared around our three
value drivers:
    Receiving regulatory approvals of our second
commercial therapy, Pombiliti    + Opfolda   , in the
United States, European Union, and the United
Kingdom
    Increasing access to Galafold with over 2,400
people living with Fabry disease around the world
    Delivering on our commitment of non-GAAP
pro   tability in the fourth quarter of the year
Following the approval of our second commercial
therapy, we are committed more than ever to
increasing our leadership in rare diseases and
achieving our next level of growth. A growth de   ned
by delivering our therapies to those in need, advancing
our ongoing studies to enhance our medical and
scienti   c leadership in Fabry and Pompe disease, and
leveraging our strong infrastructure to create longterm value. I am con   dent our pursuit of excellence
and innovation on behalf of people living with rare
diseases will position us for success and create value
for all our stakeholders.
As we re   ect on the past year and set our sights on
the year ahead, I would like to recognize the many
people who have made Amicus an extraordinary story
in rare disease. Thank you to the patients and their
families who inspire us, to our employees for their
passion and drive, and to you, our shareholders, for
supporting our mission.
Sincerely,
Bradley Campbell
President and Chief Executive Officer
Amicus Therapeutics 2023 Annual Report 2

Bradley L. Campbell
President and Chief Executive Officer
Amicus Therapeutics 2023 Annual Report 3

A Rare Company.
Amicus Therapeutics is a global, patient-dedicated
biotechnology company focused on developing and delivering
high-quality medicines for people living with rare diseases.
as of December 31, 2023
$399M
Net Product Sales
500+
Dedicated
Employees Globally
2 Approved
Therapies
Galafold   and Pombiliti    + Opfolda   
Global Footprint in
20+ Countries
Focused Rare Disease
Pipeline
in Fabry Disease
and Pompe Disease
Non-GAAP
Pro   tability
Achieved in Q4 20231
1. Amicus de   nes non-GAAP Net (Loss) Income as GAAP Net (Loss) Income excluding the impact of share-based compensation expense,
changes in fair value of contingent consideration, loss on impairment of assets, depreciation and amortization, acquisition related income
(expense), loss on extinguishment of debt, restructuring charges and income taxes.
Amicus Therapeutics 2023 Annual Report 4

An
Extraordinary
Story in Rare
Disease
2023
Pombiliti    + Opfolda    approved        rst
and only two-component therapy for
Late-Onset Pompe disease
2022
More than 2,000 patients
on Galafold  
2016
Galafold   approved        rst and
only approved oral treatment
option for Fabry disease
2013
Entry into biologics through
acquisition of Callidus and Pompe
enzyme replacement therapy
2007
Amicus initial public offering
(NASDAQ: FOLD)
2006
First Fabry patient treated in
an Amicus clinical trial
2002
Amicus is founded on the
pharmacological chaperone technology
from Mt. Sinai School of Medicine
Amicus, the Latin word for friend,
signi   es our collaborative approach to
developing medicines by incorporating the
patient perspective every step of the way. Our
company was founded by an entrepreneur who
embarked on a life-long journey to transform the
lives of those living with devastating conditions
when two of his children were diagnosed
with a rare disease. That spirit of empathy,
compassion, and tenacity permeates our culture
and in   uences all aspects of our approach to
advancing cutting-edge technologies.
Amicus Therapeutics 2023 Annual Report 5



 4/24/2024 Letter Continued (Full PDF)